title: The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol.
abstract: OBJECTIVE
  To explore the suitable application of MCM-41 (Mobil Composition of Matter number forty-one)-type and MCM-48-type mesoporous silica in the oral water insoluble drug delivery system.
  
  
  METHODS
  Cilostazol (CLT) as a model drug was loaded into synthesized MCM-48 (Mobil Composition of Matter number forty-eight) and commercial MCM-41 by three common methods. The obtained MCM-41, MCM-48 and CLT-loaded samples were characterized by means of nitrogen adsorption, thermogravimetric analysis, ultraviolet-visible spectrophotometry, scanning electron microscopy, transmission electron microscopy, differential scanning calorimetry and powder X-ray diffractometer.
  
  
  RESULTS
  It was found that solvent evaporation method was preferred according to the drug loading efficiency and the maximum percent cumulative drug dissolution. MCM-48 with 3D cubic pore structure and MCM-41 with 2D long tubular structure are nearly spherical particles in 300-500 nm. Nevertheless, the silica carriers with similar large specific surface areas and concentrating pore size distributions (978.66 m(2)/g, 3.8 nm for MCM-41 and 1108.04 m(2)/g, 3.6 nm for MCM-48) exhibited different adsorption behaviors for CLT. The maximum percent cumulative drug release of the two CLT/silica solid dispersion (CLT-MCM-48 and CLT-MCM-41) was 63.41% and 85.78% within 60 min, respectively; while in the subsequent 12 h release experiment, almost 100% cumulative drug release were both obtained. In the pharmacokinetics aspect, the maximum plasma concentrations of CLT-MCM-48 reached 3.63 mg/L by 0.92 h. The AUC0-∞ values of the CLT-MCM-41 and CLT-MCM-48 were 1.14-fold and 1.73-fold, respectively, compared with the commercial preparation.
  
  
  CONCLUSIONS
  Our findings suggest that MCM-41-type and MCM-48-type mesoporous silica have great promise as solid dispersion carriers for sustained and immediate release separately.
authors.affiliation: Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenhe District , Shenyang, Liaoning Province , PR China and.
authors.forename: Yanzhu
authors.initials: Y
authors.lastname: Wang
authors.forename: Lizhang
authors.initials: L
authors.lastname: Sun
authors.forename: Tongying
authors.initials: T
authors.lastname: Jiang
authors.forename: Jinghai
authors.initials: J
authors.lastname: Zhang
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.forename: Changshan
authors.initials: C
authors.lastname: Sun
authors.forename: Yihui
authors.initials: Y
authors.lastname: Deng
authors.forename: Jin
authors.initials: J
authors.lastname: Sun
authors.forename: Siling
authors.initials: S
authors.lastname: Wang
mesh_terms: D000284:Administration, Oral; D002152:Calorimetry, Differential Scanning; D000077407:Cilostazol; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D065546:Drug Liberation; D004355:Drug Stability; D008855:Microscopy, Electron, Scanning; D046529:Microscopy, Electron, Transmission; D010316:Particle Size; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry*; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet; D013499:Surface Properties; D013777:Tetrazoles / Q000008:administration & dosage* / Q000737:chemistry; D013818:Thermogravimetry; D014867:Water / Q000737:chemistry*
chemical_list: D004337:Drug Carriers; C509968:MCM-41; D013777:Tetrazoles; D014867:Water; D012822:Silicon Dioxide; D000077407:Cilostazol
keywords: Cilostazol; MCM-41; MCM-48; drug release; silica carriers; solid dispersion